- Investing Ideas
- Swedish Pharmaceuticals & Biotech Potentially Undervalued Small Caps
Swedish Pharmaceuticals & Biotech Potentially Undervalued Small Caps
Results
6
Value score of at least 4 focused on companies with a low market cap.
6 companies
Cantargia
Market Cap: SEK 517.1m
A biotechnology company, develops pharmaceuticals for treatment of cancer, inflammatory, and autoimmune diseases.
CANTA
SEK 2.08
7D
-28.7%
1Y
62.8%
Sprint Bioscience
Market Cap: SEK 357.7m
A pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden.
SPRINT
SEK 3.39
7D
-3.4%
1Y
716.9%
Double Bond Pharmaceutical International
Market Cap: SEK 12.9m
A pharmaceutical company, engages in the development and commercialization of approaches for the treatment of oncological and infectious diseases.
DBP B
SEK 0.12
7D
9.1%
1Y
-72.7%
ODI Pharma
Market Cap: SEK 59.8m
A pharmaceutical company, engages in the production and distribution of pharmaceutical cannabis and cosmetics products in Europe.
ODI
SEK 3.26
7D
-13.8%
1Y
61.4%
Guard Therapeutics International
Market Cap: SEK 27.2m
A clinical-stage biotechnology company, identifies and develops medicines to treat kidney diseases in Sweden.
GUARD
SEK 1.35
7D
0%
1Y
-92.5%
Subgen AI
Market Cap: SEK 109.0m
Develops artificial intelligence-based models and applications to control data for government and businesses.
SUBGEN
SEK 0.11
7D
-22.2%
1Y
n/a